JP Morgan Chase
STSA

JP Morgan Chase’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

JP Morgan Chase’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-46,998
Closed -$195K – 7036
2022
Q2 		$195K Buy
+46,998
New +$166K ﹤0.01% 5096
2021
Q3 		– Sell
-21,707
Closed -$153K – 6947
2021
Q2 		$153K Sell
21,707
-57,345
-73% -$309K ﹤0.01% 5369
2021
Q1 		$467K Sell
79,052
-13,901
-15% -$84.2K ﹤0.01% 4725
2020
Q4 		$429K Buy
92,953
+89,527
+2,613% +$386K ﹤0.01% 4461
2020
Q3 		$13K Sell
3,426
-13,464
-80% -$271K ﹤0.01% 5230
2020
Q2 		$486K Buy
16,890
+1,003
+6% +$23.2K ﹤0.01% 3861
2020
Q1 		$341K Buy
15,887
+14,445
+1,002% +$328K ﹤0.01% 4026
2019
Q4 		$28K Buy
+1,442
New +$20.5K ﹤0.01% 5270

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase's STSA Position: Q3 2022 in Review

JP Morgan Chase sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2022, closing a stake of 46,998 shares — an estimated $195K sold.

JP Morgan Chase first reported a position in STSA in Q4 2019 and held it in 8 quarters. The position peaked at $486K in Q2 2020. 41 funds tracked by Wall St. Rank hold STSA as of Q3 2022.

  • JP Morgan Chase reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • JP Morgan Chase sold 46,998 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $195K.
  • JP Morgan Chase first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • JP Morgan Chase's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $486K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.